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Evaluating the cost-effectiveness of insulin detemir 
versus neutral protamine Hagedorn insulin in 
patients with type 1 or type 2 diabetes in the UK 
using a short-term modeling approach
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Background: To estimate the short-term cost-effectiveness of insulin detemir (IDet) versus 
neutral protamine Hagedorn (NPH) insulin based on the incidence of non-severe hypoglycemia 
and changes in body weight in subjects with type 1 diabetes (T1D) or type 2 diabetes (T2D) 
in the UK.
Methods: A model was developed to evaluate cost-effectiveness based on non-severe hypo-
glycemia, body mass index, and pharmacy costs over 1 year. Published rates of non-severe 
hypoglycemia were employed in the T1D and T2D analyses, while reduced weight gain with 
IDet was modeled in the T2D analysis only. Effectiveness was calculated in terms of quality-
adjusted life expectancy using published utility scores. Pharmacy costs were captured using 
published prices and defined daily doses. Costs were expressed in 2016 pounds sterling (GBP). 
Sensitivity analyses were performed (including probabilistic sensitivity analysis).
Results: In T1D, IDet was associated with fewer non-severe hypoglycemic events than NPH 
insulin (126.7 versus 150.8 events per person-year), leading to an improvement of 0.099 quality-
adjusted life years (QALYs). Costs with IDet were GBP 60 higher, yielding an incremental 
cost-effectiveness ratio (ICER) of GBP 610 per QALY gained. In T2D, mean non-severe hypo-
glycemic event rates and body weight were lower with IDet than NPH insulin, leading to a total 
incremental utility of 0.120, accompanied by an annual cost increase of GBP 171, yielding an 
ICER of GBP 1,422 per QALY gained for IDet versus NPH insulin.
Conclusion: Short-term health economic evaluation showed IDet to be a cost-effective alterna-
tive to NPH insulin in the UK due to lower rates of non-severe hypoglycemia (T1D and T2D) 
and reduced weight gain (T2D only).
Keywords: cost-benefit analysis, insulin, diabetes mellitus type 1, diabetes mellitus type 2, 
hypoglycemia
Plain language summary
The present study evaluated the cost-effectiveness of neutral protamine Hagedorn (NPH) insulin 
relative to insulin detemir ([IDet] Levemir®; Novo Nordisk A/S, Bagsværd, Denmark) from the 
perspective of the UK National Health Service (NHS). Although the two insulins have slightly 
different durations of action, both are widely used as the “basal” component of a patient’s insulin 
regimen, providing glycemic control over the course of the day (as opposed to “bolus” insulin, 
which is administered at mealtimes in patients with type 1 diabetes or more advanced type 2 
diabetes). Numerous clinical studies have demonstrated that IDet results in less day-to-day 
variation in blood glucose levels, fewer episodes of hypoglycemia (very low blood glucose), 
and less weight gain relative to NPH insulin. In the UK, however, NPH insulin is currently 46% 
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cheaper than IDet on a per-unit basis (£0.015 versus £0.028 when 
each insulin dose is purchased in a pen cartridge for injection). As 
NHS England faces increasing budget constraints, balancing the 
additional cost of IDet with the clinical benefits it provides is an 
important aspect of ensuring good value for money for the NHS. 
Here, we used a short-term (1 year) computer model to establish if 
differences between IDet and NPH insulin in terms of insulin dos-
ing, hypoglycemia, and, in type 2 diabetes, body mass index, were 
worth the additional cost to the NHS.
Introduction
Long-term studies such as the Diabetes Control and Com-
plications Trial (DCCT) in type 1 diabetes have shown 
that improved glycemic control leads to improved long-
term outcomes.1 Long-term studies in type 2 diabetes, 
such as the United Kingdom Prospective Diabetes Study 
(UKPDS), have similarly shown unequivocal benefits of 
improved glycemic control in terms of microvascular and 
macrovascular benefits.2 Epidemiological studies have also 
demonstrated reduced incidence of macrovascular com-
plications with improved glycemic control.3 Lower blood 
glucose levels are, however, accompanied by an increased 
risk of hypoglycemia. In the DCCT, patients in the intensive 
treatment group were exposed to a threefold higher rate of 
severe hypoglycemia (61.2 events per 100 patient years 
versus 18.7 events per 100 patient years in the conventional 
treatment group).4 The severity of hypoglycemic episodes 
ranges from relatively mild, which can be remedied by 
eating fast-acting carbohydrates, through to severe events 
that can result in seizure, coma, and occasionally death. 
Real-world data from the UK collected from 466 patients 
with type 1 diabetes over a period of 4 weeks (7-day recall 
period) indicated an average non-severe hypoglycemic event 
rate in individuals with type 1 diabetes of 126.7 events per 
patient per year, equivalent to experiencing an event every 
3 days.5 While hypoglycemia is less frequent in patients 
with type 2 diabetes than patients with type 1 diabetes, 
hypoglycemia becomes progressively more frequent as the 
disease progresses, with the same study reporting a rate of 
41.5 events per patient per year in insulin-using patients 
with type 2 diabetes.5,6 Evidence from a variety of sources 
has also shown that hypoglycemic events reduce quality 
of life and workplace productivity,7–14 and increase health 
care resource utilization.11
Long-acting insulin analogues such as IDet can reduce 
the rate of non-severe hypoglycemia in individuals with 
type 1 or type 2 diabetes relative to NPH insulin. Indeed, 
several trials have provided evidence that treatment with 
IDet results in predictable glycemic control with less 
day-to-day variation, fewer hypoglycemic episodes, and 
decreased weight gain in comparison with NPH insulin.15–21 
The clinical benefit of reduced non-severe hypoglycemia 
comes at an additional cost, however, with drug costs asso-
ciated with IDet being higher than those of NPH insulin 
in most countries.
The present modeling analysis is therefore designed to 
provide an insight into whether the additional cost of IDet is 
justified in terms of the clinical benefit it provides in patients 
with type 1 or type 2 diabetes.
Methods
A cost-effectiveness model was developed in Microsoft 
Excel 2010 to evaluate the cost-effectiveness of IDet relative 
to NPH insulin in patients with type 1 or type 2 diabetes. 
The model adopted the perspective of a UK health care payer 
(the National Health Service), and the base-case analysis 
was conducted over a 1-year time horizon, negating the 
need for discounting of cost or effectiveness outcomes. 
The 1-year time horizon was selected on the grounds that 
NPH insulin and IDet both have the same mechanism of 
action, and any differences in the long-term incidence of 
diabetes complications could be mitigated by adjusting the 
respective insulin doses.
The model captured insulin, needle and self-monitoring 
of blood glucose (SMBG) costs, costs of other antidiabetes 
therapies, and costs associated with non-severe hypogly-
cemic events. All costs were expressed in 2016 pounds 
sterling (GBP). Concomitant medication costs such as 
antihypertensive and lipid lowering agents were assumed to 
be equivalent in both arms and excluded from the analysis. 
Differences in glycemic control and other risk factors such 
as blood pressure were also excluded on the grounds that 
glycemic control can be achieved by simply titrating up the 
dose of insulin and high blood pressure can be controlled 
using relatively low-cost antihypertensives. However, dif-
ferences in body mass index (BMI) were captured in the 
analysis of type 2 diabetes to evaluate the effect on health-
related quality of life.
Hypoglycemia rates
Hypoglycemia rates in patients with type 1 or type 2 diabe-
tes using IDet were taken from a 2013 UK-specific study on 
self-reported rates of hypoglycemia in 1,038 adult patients 
with type 1 (n=466) or type 2 (n=572) diabetes.5 In the type 
1 base-case analysis, the non-severe hypoglycemic event 
rate for patients receiving NPH insulin was calculated by 
applying a rate ratio of 1.19 (the reciprocal of 0.84) to the 
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Cost-effectiveness of NPH versus insulin detemir
UK base rate of 126.7 events per patient year with IDet, 
yielding a deterministic rate estimate with NPH insulin of 
150.8 events per patient year. The rate ratio was taken from 
a meta-analysis of six clinical trials of IDet versus NPH 
insulin comprising over 2,109 subjects with type 1 diabetes 
as part of a health technology assessment by the Canadian 
Agency for Drugs and Technology in Health (CADTH) 
published in 2008.22 The mean reciprocal rate ratio of 1.19 
was used in the base-case analysis and the correspond-
ing 95% CI of 1.03–1.35 was used both for probabilistic 
sensitivity analysis (PSA) and to calculate the non-severe 
hypoglycemic event rate on NPH insulin for “pessimistic” 
and “optimistic” scenarios, respectively.
The type 2 base-case analysis utilized an overall hypogly-
cemia relative rate from the same CADTH meta-analysis as 
used in the analysis of type 1 diabetes, with a mean rate ratio 
of 0.59 for IDet relative to NPH insulin. The reciprocal rate 
ratio of 1.69 (95% CI 1.39–2.08) was applied to the IDet base 
rate of 41.5 events per patient year from the UK self-report 
study, to give a deterministic rate estimate of 70.34 events 
per patient year with NPH insulin.
Severe hypoglycemic events were not included in either 
the type 1 or type 2 analyses as the same CADTH meta-
analysis reported a non-significant difference between 
treatments, with a rate ratio for severe hypoglycemia of 
0.95 (95% CI 0.65–1.38) in patients on IDet relative to NPH 
insulin.22
Insulin dosing and concomitant 
medications
Insulin doses in the analysis of patients with type 1 diabetes 
were derived from a population of 437 adults enrolled in the 
Dose Adjustment For Normal Eating (DAFNE) structured 
education program.23 Specifically, mean basal insulin dos-
ing was modeled at 24.35 IU per day, while mean bolus 
insulin dosing was assumed to be 27.88 IU per day. In the 
type 1 base-case analysis, dosing of IDet and NPH insulin 
was assumed to be equivalent. In the type 2 (basal-only) 
analysis, insulin doses were modeled in line with data from 
the PREDICTIVE study, assuming doses of 0.47 IU/kg/
day for NPH insulin and 0.59 IU/kg/day for IDet and based 
on a mean body weight of 76 kg in line with the baseline 
weight of the UKPDS insulin starter group.2,24 In addition 
to insulin, patients with type 2 diabetes were assumed to 
take 2,000 mg of metformin a day and 60 mg of gliclazide 
in line with the World Health Organization defined daily 
doses of metformin and sulfonylurea, respectively.
Self-monitoring of blood glucose
Patients with type 1 diabetes were assumed to perform SMBG 
tests four times daily in line with 2015 guidance from the 
National Institute for Health and Care Excellence, which spe-
cifically recommends “testing at least 4 times a day, including 
before each meal and before bed” in patients with type 1 
diabetes without any specific need to test more frequently.25 
This is likely to be a conservative estimate as many patients 
meet the criteria for more frequent testing, such as involve-
ment in sports or high-risk activities, impaired awareness of 
hypoglycemia, illness, pregnancy, or failure to achieve the 
desired glycated hemoglobin (HbA1c) target. Patients with 
type 2 diabetes were assumed to perform SMBG three times 
a day on 2 days a week (an average of 0.86 tests per day) in 
line with the DiGEM trial, which investigated the effect of 
different SMBG strategies on glycemic control in patients 
with type 2 diabetes.26,27
Quality of life
In the base-case analysis, a quality of life disutility of –0.004 
was associated with each non-severe hypoglycemic event, 
based on a 2013 study by Evans et al. 28 The type 2 diabetes 
analysis also associated a disutility with increased BMI derived 
from the CADTH meta-analysis. The difference in body weight 
reported in the meta-analysis (0.96 kg higher with NPH insulin 
than with IDet) was converted to a mean difference in BMI 
using a mean height of 1.72 m, and a disutility of –0.0061 per 
additional BMI unit was applied based on the time trade-off 
model coefficient for each BMI unit over 25 kg/m2 reported by 
Bagust and Beale.29,30 Baseline quality of life with no complica-
tions in patients with type 1 or type 2 diabetes was taken to be 
0.81 based on a 2011 meta-analysis by Lung et al.31
Unit costs
Costs of insulin (NPH, IDet, and bolus insulin in the type 
1 analysis), metformin, and sulfonylurea were taken from 
the British National Formulary (Table 1). Costs of needles, 
SMBG test strips, and lancets were taken from the NHS 
Business Services Authority. The cost of hypoglycemic events 
was taken from a recent analysis of the cost of non-severe 
hypoglycemia in 10 European countries including the UK.32 
The analysis was based on data from the Hypoglycaemia in 
Insulin Treated Patients (HIT) study,5 and captured costs of 
additional SMBG test strip use and contact with health care 
professionals (either by telephone consultation, or visit to a 
nurse or primary care physician) in a country-specific propor-
tion of patients with type 1 or type 2 diabetes.
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Sensitivity analysis
A series of sensitivity analyses were conducted to establish 
the magnitude by which model outcomes changed in response 
to changes in individual input parameters. In the type 2 dia-
betes analyses, insulin doses were changed to match those 
reported by Eliasson et al (29.9 IU/day with NPH insulin and 
42.1 IU/day with IDet).33 In both type 1 and type 2 diabetes 
analyses, the hypoglycemia rate ratio was set at 0.78 (from 
Bartley et al) in the type 1 diabetes analysis and 0.7 (from 
Tajima et al) in the type 2 diabetes analysis, compared to 0.84 
and 0.59 in the respective base-case analyses.21,34 The base 
rates of hypoglycemia in the IDet arm were also modified to 
match those reported by the UK Hypoglycemia Study Group 
(UKHSG; 35.5 events per patient per year for type 1 diabetes 
and 4.08 events per patient per year for type 2 diabetes).35 
Further analyses were conducted in which the quality of 
life disutility associated with each hypoglycemic event was 
changed to values from Currie et al 10 (−0.0035), Levy et al 
(−0.0033, SD=0.0004),7 and using a diminishing marginal 
hypoglycemia utility model published by Lauridsen et al.36 
Finally, the disutility associated with increased BMI was 
abolished in an analysis around the type 2 diabetes base case.
Results
Using non-severe hypoglycemia rate ratios and body weight 
differences from a recent CADTH meta-analysis, the present 
analysis showed IDet to be cost-effective relative to NPH 
insulin in patients with either type 1 or type 2 diabetes in the 
UK setting over a 1-year time horizon.
In patients with type 1 diabetes, the deterministic analysis 
showed an increase in costs of GBP 60 with IDet relative to 
NPH insulin over a 1-year time horizon (GBP 1,301 relative 
to GBP 1,241). The reduced rate of hypoglycemia resulted 
in a quality-adjusted life expectancy gain of 0.099 quality-
adjusted life years (QALYs), resulting in an incremental 
cost-effectiveness ratio (ICER) of GBP 610 per QALY 
gained (Table 2). The equivalent analysis in patients with 
type 2 diabetes showed a cost increase of GBP 171 with IDet 
relative to NPH insulin over a 1-year time horizon (GBP 798 
relative to GBP 627). The reduced rate of hypoglycemia with 
IDet combined with the smaller increase in BMI resulted in 
a gain of 0.120 QALYs, resulting in an ICER of GBP 1,422 
per QALY gained.
PSA yielded similar outcomes to the deterministic 
base-case analyses with incremental quality-adjusted life 
expectancy of 0.101 QALYs (standard deviation [SD] 0.038 
QALYs) and incremental costs of GBP 59 (SD GBP 45) in the 
type 1 analysis, resulting in an ICER of GBP 587 per QALY 
gained. In the type 2 diabetes PSA, incremental costs were 
GBP 173 (SD GBP 202) and incremental quality-adjusted life 
expectancy was 0.123 QALYs (SD 0.028 QALYs), resulting 
in an ICER of GBP 1,408 per QALY gained. Results of the 
10,000 model iterations were plotted on a scatterplot, and 
cost-effectiveness acceptability curves were generated over a 
range of willingness-to-pay (WTP) thresholds (Figures 1– 4). 
At a WTP threshold of GBP 10,000 per QALY gained, there 
was a 99.9% likelihood that detemir would be cost-effective 
relative to NPH insulin in patients with type 1 diabetes. In 
patients with type 2 diabetes, there was a 100% likelihood 
of cost-effectiveness at the same WTP threshold.
One-way sensitivity analysis results showed the model 
to be sensitive to assumptions around the hypoglycemia 
base rate and rate ratios, and the use of a per-event utility 
model versus a diminishing marginal utility (DMU) model 
(Table 3). Notably, setting the hypoglycemia rate ratio to 
0.78 resulted in an analysis in which IDet was relatively 
more effective than NPH insulin in type 1 diabetes, with 
an incremental quality-adjusted life expectancy of 0.147 
QALYs and additional costs of GBP 35 with IDet,  resulting 
in an ICER of GBP 238 per QALY gained. In the type 2 
Table 1 Unit costs in the base-case analysis
Cost Cost basis Reference
NPH insulin (GBP per IU) 0.015 ,QVXODWDUG3HQÀOO® cartridge 100 IU/mL, 5×3 mL BNF, September 2016
Insulin detemir (GBP per IU) 0.028 Levemir®3HQÀOO® cartridge 100 IU/mL, 5×3 mL BNF, September 2016
Bolus insulin (GBP per IU) 0.019 NovoRapid® 3HQÀOO® cartridge 100 IU/mL, 5×3 mL BNF, September 2016
Metformin (GBP per gram) 0.027 Metformin tablets, 850 mg, 56 tablet pack BNF, September 2016
Gliclazide (GBP per milligram) 0.003 Gliclazide tablets, 40 mg, 28 tablet pack BNF, September 2016
Needles (GBP per needle) 0.03 BD Micro-Fine 0.3 mm/30 gauge, 200 needle pack NHS BSA, September 2016
SMBG test strip (GBP per strip) 0.319 Accu-Chek Aviva, 50 strip pack NHS BSA, September 2016
Lancet (GBP per lancet) 0.049 FastClix (Roche Diabetes Care Ltd), 204 lancet pack NHS BSA, September 2016
Hypoglycemic event T1D (GBP) 2.193 Additional strips and HCP contacts 33
Hypoglycemic event T2D (GBP) 3.066 Additional strips and HCP contacts 33
Abbreviations: NPH, neutral protamine Hagedorn; BD, Becton Dickinson; GBP, 2016 pounds sterling; HCP, health care professional; IU, international units; NHS BSA, 
National Health Service Business Services Authority; SMBG, self-monitoring of blood glucose; BNF, British National Formulary; T1D, type 1 diabetes; T2D, type 2 diabetes.
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diabetes analysis, reducing the hypoglycemia rate differ-
ence to that reported by Tajima et al increased the ICER to 
GBP 2,735 per QALY gained.34 Changing the hypoglycemia 
disutilities to values from studies other than Evans et al on 
a per-event basis resulted in relatively small changes in the 
ICER, while switching to use the Lauridsen et al’s dimin-
ishing hypoglycemia utility model increased the ICER to 
GBP 13,578 per QALY gained and GBP 14,533 per QALY 
Table 2 Cost-effectiveness of insulin detemir versus NPH insulin in the UK
NPH insulin 
cost (GBP)
Insulin detemir  
cost (GBP)
Incremental 
cost (GBP)
NPH  
effectiveness 
(QALYs)
Insulin detemir 
effectiveness 
(QALYs)
Incremental 
effectiveness 
(QALYs)
ICER (GBP per 
QALY gained)
Type 1 diabetes 1,241 1,301 +60 0.192 0.291 0.099 610
Type 2 diabetes 627 798 +171 0.520 0.640 0.120 1,422
Abbreviations: GBP, 2016 pounds sterling; NPH, neutral protamine Hagedorn; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
Figure 1 Cost-effectiveness scatter plot for insulin detemir relative to NPH insulin in patients with type 1 diabetes.
Abbreviations: NPH, neutral protamine Hagedorn; QALY, quality-adjusted life year; GBP, 2016 pounds sterling.
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Figure 2 Cost-effectiveness acceptability curve for insulin detemir relative to NPH insulin in patients with type 1 diabetes.
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gained in the analyses of type 1 and type 2 diabetes, respec-
tively.28,36 Changing the insulin dose assumptions in the type 2 
diabetes analysis based on Eliasson et al resulted in an ICER 
of GBP 1,459 per QALY gained, a slight increase over the 
base-case analysis.33 Finally, by using rates of hypoglycemia 
from the UKHSG substantially increased the ICERs from 
GBP 610 per QALY gained to GBP 3,550 per QALY gained 
in the type 1 analysis, and from GBP 1,422 per QALY gained 
to GBP 18,429 per QALY gained in the type 2 analysis.
Discussion
The modeling approach used in the present analyses demon-
strated that IDet would be considered  cost-effective relative to 
NPH insulin in patients with type 1 or type 2 diabetes in the 
UK. The analysis only captured differences in costs associated 
with antidiabetic medications and non-severe hypoglycemic 
events, and did not take into consideration other differences 
such as severe hypoglycemia and glycemic control. Needles 
and SMBG were also captured in the analysis, but were not 
a driver of differences between IDet and NPH insulin. The 
modeling approach is likely to be conservative with regard 
to the incremental cost-effectiveness of IDet relative to NPH 
insulin. For instance, randomized controlled trials and meta-
analyses have demonstrated improved glycemic control with 
IDet relative to NPH, including a 2011 systematic review and 
meta-analysis of 10 randomized controlled trials  including 
3,825 patients, which showed a weighted mean HbA1c dif-
ference of –0.073% (p=0.021) with IDet relative to NPH and 
Figure 3 Cost-effectiveness scatter plot for insulin detemir relative to NPH insulin in patients with type 2 diabetes.
Abbreviations: NPH, neutral protamine Hagedorn; QALY, quality-adjusted life year; GBP, 2016 pounds sterling.
–1000
Incremental quality-adjusted life expectancy (QALYs)
In
c
re
m
e
n
ta
l 
c
o
s
t 
(G
B
P
)
1000
–600
650
–800
800
–400
400
–200
–0.1–0.2–0.3
200
0
0.0 0.1 0.2 0.3
Figure 4 Cost-effectiveness acceptability curve for insulin detemir relative to NPH insulin in patients with type 2 diabetes.
Abbreviations: NPH, neutral protamine Hagedorn; QALY, quality-adjusted life year; GBP, 2016 pounds sterling.
6,000 8,000 10,0000
0
10
20
30
40
50
60
70
80
90
100
2,000 4,000
Willingness-to-pay threshold (GBP per QALY gained)
L
ik
e
lih
o
o
d
 t
h
a
t 
in
s
u
lin
 d
e
te
m
ir
 w
o
u
ld
 b
e
c
o
s
t-
e
ff
e
c
ti
v
e
 r
e
la
ti
v
e
 t
o
 N
P
H
 (
%
)
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
28
.1
30
 o
n 
31
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
223
Cost-effectiveness of NPH versus insulin detemir
a relative risk of severe hypoglycemia of 0.665 (p<0.001) in 
patients with type 1 diabetes.37 While this is a limitation of 
the analyses presented here, the decision to exclude severe 
hypoglycemia and improved glycemic control resulted in 
a highly conservative analysis over a longer time horizon.
In the analyses of both type 1 and type 2 diabetes, reduc-
tions in the rate of non-severe hypoglycemia with IDet 
relative to NPH insulin were derived from a meta-analysis 
performed by CADTH.22 While the meta-analysis reported 
an overall hypoglycemia rate ratio for IDet relative to NPH 
insulin of 0.84 (95% CI 0.74–0.97) in patients with type 1 
diabetes, non-severe hypoglycemia was not reported sepa-
rately and the overall rate was therefore used as a proxy. This 
was a conservative approach compared with using the rate 
ratio from the Bartley et al clinical trial (mean rate ratio 0.78, 
95% CI 0.52–1.16), which was investigated in sensitivity 
analysis and reduced the ICER to GBP 238 per QALY gained 
in patients with type 1 diabetes.21
In type 2 diabetes, the selected rate ratio of 0.59 (95% 
CI 0.48–0.72) for non-severe hypoglycemia was based on 
the CADTH meta-analysis of overall hypoglycemia rates in 
patients with type 2 diabetes using oral antidiabetic agents 
in combination with IDet or NPH insulin.22 While the meta-
analysis finding was significant, the outcome was based on 
just three randomized controlled trials, which exhibited a high 
degree of heterogeneity in the reported outcomes (I2=86.9% 
based on a chi-squared test outcome of 15.28 over 2 degrees 
of freedom).22,34,38,39 The CADTH analysis authors noted that 
the heterogeneity may have been driven by the dosing fre-
quency of IDet and NPH, which was not consistent across the 
three studies. Despite the high degree of heterogeneity, the 
studies were all directionally in agreement, with mean rate 
ratios of 0.52, 0.54, and 0.70 for IDet relative to NPH insulin 
in the Philis-Tsimikas et al, Hermansen et al, and Tajima et al 
studies, respectively.22,34,38,39 CADTH also noted that the dif-
ference was driven by a significant reduction in the frequency 
but not the risk of overall hypoglycemia, implying that the 
reductions were a result of reduced rates of hypoglycemia in 
patients prone to experiencing hypoglycemia rather than a 
reduction in the proportion of patients having hypoglycemic 
events.22 Such a finding would be congruous with the findings 
of trials such as HypoAna, which demonstrated significant 
reductions in hypoglycemia rates in patients prone to recur-
rent severe hypoglycemia.40 Even these reductions may be 
conservative relative to the differences observed in routine 
clinical practice, as Phase III regulatory studies of insulin 
(which need to demonstrate safety) tend to exclude patients 
who are prone to hypoglycemia.
Sensitivity analyses showed that the results were most 
sensitive to the use of DMU model to evaluate the effect 
of hypoglycemia on the quality of life. Such models reduce 
the incremental disutility associated with each additional 
hypoglycemic event as overall frequency increases, in this 
case using a weighted power function to determine the exact 
Table 3 One-way sensitivity analysis results
NPH insulin 
cost (GBP)
Insulin  
detemir  
cost (GBP)
Incremental 
cost (GBP)
NPH  
effectiveness 
(QALYs)
Insulin  
detemir 
effectiveness 
(QALYs)
Incremental 
effectiveness 
(QALYs)
ICER (GBP 
per QALY 
gained)
Type 1 diabetes
Base case 1,241 1,301 +60 0.192 0.291 +0.099 610
Hypoglycemia rate ratio of 0.7821 1,266 1,301 +35 0.144 0.291 +0.147 238
Levy et al hypoglycemia disutility7 1,241 1,301 +60 0.312 0.392 +0.080 757
Currie et al hypoglycemia disutility10 1,241 1,301 +60 0.282 0.367 +0.084 714
Diminishing hypoglycemia utility 1,241 1,301 +60 0.733 0.737 +0.004 13,578
UKHSG base hypoglycemia rate 1,003 1,101 +98 0.637 0.664 +0.028 3,550
Type 2 diabetes
Base case 627 798 +171 0.520 0.640 +0.120 1,422
No BMI disutility 627 798 +171 0.522 0.640 +0.118 1,446
Hypoglycemia rate ratio of 0.739 593 798 +205 0.565 0.640 +0.075 2,735
Levy et al hypoglycemia disutility7 627 798 +171 0.576 0.673 +0.097 1,760
Currie et al hypoglycemia disutility10 627 798 +171 0.562 0.665 +0.103 1,661
Diminishing hypoglycemia utility 627 798 +171 0.748 0.760 +0.012 14,533
Eliasson et al insulin doses33 594 770 +175 0.520 0.640 +0.120 1,459
UKHSG base hypoglycemia rate 432 683 +251 0.780 0.793 +0.014 18,429
Abbreviations: GBP, 2016 pounds sterling; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; UKHSG, UK Hypoglycemia Study Group; NPH, 
neutral protamine Hagedorn; BMI, body mass index.
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relationship.36 The authors of the DMU model noted that 
the reduced utility for additional events may be reflective of 
a range of phenomena, including patients learning to cope 
with hypoglycemia, an unwillingness to trade-off remaining 
lifetime after a certain point, or simply respondents paying 
more attention to the health-state descriptions than the event 
frequencies. The question of minimally important differ-
ences (MIDs) in quality of life should also be considered 
with regard to the DMU model, as the incremental disutil-
ity of additional hypoglycemic events in the model falls 
below the MIDs for generic instruments such as the Health 
Utilities Index, EuroQoL-5D (EQ-5D), and 36-Item Short 
Form Health Survey (SF-36).41,42 The DMU model did not 
capture any reduction in quality of life associated with the 
fear of hypoglycemia, which has been shown to be greater 
in patients with experience of hypoglycemia relative to those 
without, and greater in patients with more severe symptoms 
of hypoglycemia.43 The effects of fear may mitigate some 
of the effects of the DMU model, making the sensitivity 
analysis highly conservative. Regardless of its conservatism, 
the analyses in both type 1 and type 2 diabetes still yielded 
ICERs lower than GBP 20,000 per QALY gained.
Considerable evidence has been published supporting the 
long-term cost-effectiveness of IDet versus NPH insulin.44–46 
Whilst these more complex modeling studies are valuable 
in the absence of long-term clinical trial data, they do not 
address the requirements of health care payers for whom 
short-term cost-effectiveness is more relevant to immediate 
budget considerations. The present study addresses this need 
by presenting a transparent, short-term analysis of the cost-
effectiveness of IDet versus NPH insulin based on up-to-date 
cost data in the UK setting.
Conclusion
This short-term health economic evaluation showed IDet to 
be a cost-effective alternative to NPH insulin in both type 1 
and type 2 diabetes in the UK. This evaluation reflects the 
clinically relevant reported reductions in non-severe hypogly-
cemic episodes, particularly at night, in people with diabetes. 
In light of the challenging new National Institute for Health 
and Care Excellence HbA1c targets it may be worth starting 
longer acting insulin analogues as first line, not only in people 
with type 1 diabetes but also when initiating insulin therapy 
in type 2 diabetes patients.
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